Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
ACS Chem Biol. 2022 Jun 17;17(6):1450-1459. doi: 10.1021/acschembio.1c00990. Epub 2022 May 10.
Lectins, carbohydrate-binding proteins of nonimmune origin, bind to carbohydrates and glycan shields present on the surfaces of cells and viral spike proteins. Lectins thus hold great promise as therapeutic and diagnostic proteins, exemplified by their potent antiviral activities and the desire to engineer synthetic carbohydrate receptors based on lectin recognition principles. Here, we describe a new carbohydrate-binding architectural motif─namely, a -symmetric tyrosine-based aromatic core, present in the therapeutic lectin griffithsin (GRFT). By using structure-based amino acid substitutions, X-ray crystallography, molecular dynamics (MD) simulations, and HIV-1 neutralization assays, we show that this core is critical for potent (pM) antiviral activity and nanomolar binding to the glycan shield largely consisting of high mannose glycans. Crystal structures and MD simulations show that CH-π interactions stabilize the aromatic cluster to maintain the three pseudo-symmetric carbohydrate-binding sites, nonaromatic amino acid substitutions (Tyr to Ala) abrogate antiviral activity, and increasing the aromatic CH-π edge-to-centroid interface via a Tyr to Trp substitution yields a GRFT variant with improved potency and increased residence time of Man-9 observed in MD simulations. NMR titrations of a Tyr-to-Ala variant indicate that disruption of the aromatic prevents the intermolecular crosslinking between two equivalents of Man-9 and one carbohydrate-binding face observed in wild-type GRFT and known to be critical for picomolar potency of this lectin. This -symmetric aromatic core defines a new recognition motif for the design of carbohydrate receptors and suggests principles for engineering known lectins to have increased affinity and stability.
凝集素是一类非免疫来源的碳水化合物结合蛋白,能够与细胞表面的碳水化合物和聚糖外壳以及病毒刺突蛋白结合。因此,凝集素作为治疗和诊断蛋白具有很大的应用潜力,其强大的抗病毒活性以及基于凝集素识别原理设计合成碳水化合物受体的愿望就是很好的例证。在这里,我们描述了一种新的碳水化合物结合结构基序,即存在于治疗性凝集素 griffithsin(GRFT)中的 -对称酪氨酸基芳香核。通过使用基于结构的氨基酸取代、X 射线晶体学、分子动力学(MD)模拟和 HIV-1 中和测定,我们表明该核对于有效的(pM)抗病毒活性和纳米摩尔结合到主要由高甘露糖聚糖组成的聚糖外壳至关重要。晶体结构和 MD 模拟表明,CH-π 相互作用稳定了芳香簇以维持三个拟对称碳水化合物结合位点,非芳香氨基酸取代(Tyr 到 Ala)会使抗病毒活性丧失,通过 Tyr 到 Trp 的取代增加芳香 CH-π 边缘到质心的界面,从而得到一种 GRFT 变体,其对 Man-9 的结合亲和力增强,在 MD 模拟中观察到的停留时间延长。对 Tyr 到 Ala 变体的 NMR 滴定表明,破坏芳香性会阻止在野生型 GRFT 中观察到的两个等当量的 Man-9 与一个碳水化合物结合面之间的分子间交联,这被认为是该凝集素具有皮摩尔效价的关键。这种 -对称的芳香核定义了一种新的碳水化合物受体设计识别基序,并为基于已知凝集素设计具有更高亲和力和稳定性的方法提供了原理。